血小板压积可作为预测慢性乙型肝炎肝纤维化的潜在指标

StephenW

Journal Summaries in Internal Medicine
Plateletcrit as a potential index for predicting liver fibrosis in chronic hepatitis B

Journal of Viral Hepatitis — Wang J, Xia J, Yan X, et al. | January 28, 2020

Researchers examined the predictive value of plateletcrit (PCT) for liver fibrosis in patients with chronic hepatitis B (CHB). Inclusion of 567 treatment-naïve CHB patients with available liver biopsies was done; of these, 378 patients formed a derivation cohort and 189 formed a validation cohort. In the derivation cohort, they noted lower PCT in CHB patients with S2-S4 (0.14%), S3-S4 (0.13%) and S4 (0.12%) than patients with S0-S1 (0.17%), S0-S2 (0.17%) and S0-S3 (0.16%), respectively. Findings suggest an independent predictive value of PCT for significant fibrosis (≥ S2), advanced fibrosis (≥ S3) and cirrhosis (S4). Higher AUROC was generated with PCT than the aspartate transaminase-to-platelet ratio index (APRI) in recognizing advanced fibrosis and cirrhosis, while in recognizing significant fibrosis, this was comparable with APRI. PCT and fibrosis-4 score (FIB-4) had comparable diagnostic value for predicting significant fibrosis, advanced fibrosis and cirrhosis. These findings support that in CHB patients, PCT is a simple and inexpensive indicator for liver fibrosis. PCT is identified to be as good or better than other more complex tools for staging liver fibrosis in CHB patients.

StephenW

内科杂志摘要
血小板压积可作为预测慢性乙型肝炎肝纤维化的潜在指标

病毒性肝炎杂志—王J，夏J，严X等。 | 2020年1月28日

研究人员检查了血小板计数（PCT）对慢性乙型肝炎（CHB）患者肝纤维化的预测价值。纳入567例未接受过治疗的CHB患者并进行了肝活检；其中，有378名患者组成了派生队列，有189名患者组成了验证队列。在派生队列中，他们指出，S2-S4（0.14％），S3-S4（0.13％）和S4（0.12％）的CHB患者的PCT低于S0-S1（0.17％），S0 -S2（0.17）的患者％）和S0-S3（0.16％）。研究结果表明，PCT对明显的纤维化（≥S2），晚期纤维化（≥S3）和肝硬化（S4）具有独立的预测价值。 PCT产生的AUROC在识别晚期纤维化和肝硬化方面比天冬氨酸转氨酶与血小板比率指数（APRI）高，而在识别出明显的纤维化方面，这与APRI相当。 PCT和fibrosis-4评分（FIB-4）在预测显着纤维化，晚期纤维化和肝硬化方面具有可比的诊断价值。这些发现支持了在CHB患者中，PCT是肝纤维化的一种简单且便宜的指标。 PCT被认为比其他更复杂的工具能够更好地诊断CHB患者的肝纤维化。

StephenW

https://onlinelibrary.wiley.com/ ... 7gkPdVcrKL7Lg%3D%3D